AMARIN CORP PLC\UK Foreign Currency Transaction Gain (Loss), Realized
AMARIN CORP PLC\UK (AMRN) reported Foreign Currency Transaction Gain (Loss), Realized of -$700.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ForeignCurrencyTransactionGainLossRealized · last filed 2026-03-02
- AMARIN CORP PLC\UK foreign currency transaction gain (loss), realized for fiscal 2025 was -$700.00K, a 187.50% decline from fiscal 2024.
- AMARIN CORP PLC\UK foreign currency transaction gain (loss), realized for fiscal 2024 was $800.00K.
- AMARIN CORP PLC\UK foreign currency transaction gain (loss), realized for fiscal 2023 was -$2.60M.
- AMARIN CORP PLC\UK foreign currency transaction gain (loss), realized for fiscal 2022 was -$700.00K.
| Period end | Foreign Currency Transaction Gain (Loss), Realized 12 month |
|---|---|
| 2025-12-31 | -$700.00K 10-K · filed 2026-03-02 |
| 2024-12-31 | $800.00K 10-K · filed 2026-03-02 |
| 2023-12-31 | -$2.60M 10-K · filed 2026-03-02 |
| 2022-12-31 | -$700.00K 10-K · filed 2025-03-12 |
| 2021-12-31 | -$600.00K 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |